Immune Checkpoint Inhibitor Toxicities
Practical knowledge and skills are required to manage the needs of the growing patient population treated with ICIs, particularly as our understanding of best practices for addressing complex toxicities evolves.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Pharmacy Updates: Assessment and Management of CAR T-Cell Related Toxicities
CAR T-cell products have the ability to completely change the treatment paradigm for hematologic malignancies.  These therapies are associated with life-threatening toxicities that require rapid intervention. Newly published consensus statements to better define and grade these toxicities should be incorporated into clinical practice.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date August 25, 2020